Tuesday, June 7, 2011

Vaxart starts early-stage oral vaccine trial

Vaccine delivery company Vaxart Inc. started dosing the first volunteers in a 54-patient Phase I safety trial of its oral vaccine, designed to protect against a strain of the Avian flu.
The trial is important for the San Francisco company, said founder and Chief Scientific Officer Sean Tucker, because if the vaccine proves safe in this first trial of the company’s technology, “we can expect that later vaccines using the same Vaxart technology will also be safe.”

No comments:

Post a Comment